IL18 and acute respiratory distress syndrome: Similarly, nanochemically modified tetracycline‐3 has emerged as a potent inhibitor of NLRP3 signalling, reducing IL‐1β and IL‐18 levels in both plasma and BALF, ultimately mitigating lung inflammation in ALI mouse models.70